DERAMCICLANE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H31NO
Molecular Weight	301.4662
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C3=CC=CC=C3

InChI

InChIKey=QOBGWWQAMAPULA-RLLQIKCJSA-N

InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H31NO
Molecular Weight	301.4662
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19963003 | https://www.ncbi.nlm.nih.gov/pubmed/15949921 | https://www.ncbi.nlm.nih.gov/pubmed/9551765

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

Approval Year

PubMed

Title	Date	PubMed
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze.	2001 Jan	11271409
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.	2002 Mar	11849919
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.	2002 Mar	11849912
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.	2008 Jan	17971064
Deramciclane improves object recognition in rats: potential role of NMDA receptors.	2010 Feb	19963003
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.	2010 Mar	19720112

Patents

Sample Use Guides

In Vivo Use Guide

60 mg/day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:53 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:53 GMT 2023`
Record UNII	O5KFK61E74
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DERAMCICLANE

Official Name

English

deramciclane [INN]

Common Name

English

DERAMCICLANE [MI]

Common Name

English

Deramciclane [WHO-DD]

Common Name

English

Code System Code Type Description

INN

6838